Exploration of the strengths and successes of new genetics in childhood disorders, and the ethical and operational challenges around testing patients, will be the topic of the Harvard Catalyst Child Health Program’s inaugural symposium Transforming Child Health Through Genome Biology on Tuesday, Oct. 8.

The afternoon program, scheduled from 2:00 to 5:30 p.m., will be held at the Joseph B. Martin Conference Center, and will feature speakers Alan Guttmacher, director of the National Institute of Child Health and Human Development at the National Institutes of Health, and Diane Bianchi, executive director of the Mother Infant Research Institute at Tufts Medical Center, along with Joshua Boger, founder and former CEO of Vertex Pharmaceuticals.

In addition to exploring the topic of child health and genome biology, the symposium will convene researchers from across Harvard and affiliated hospitals to promote collaborative work and innovation on topics relevant to children and child health.

Registration is required.

Harvard Catalyst’s Child Health Program works to foster the development of programs, resources, and strategies that support innovative and collaborative research to improve the health and well-being of children. The program works across Harvard University, its affiliated institutions, and the national CTSA Consortium.